About MiNK Therapeutics, Inc. - Common Stock (INKT)
Mink Therapeutics Inc is a biotechnology company focused on developing innovative therapeutic solutions to address unmet medical needs. The company specializes in creating advanced treatments targeting various diseases and conditions by leveraging cutting-edge technologies in drug discovery and development. With a commitment to enhancing patient outcomes, Mink Therapeutics aims to bring novel therapies from the lab to the clinic, fostering improvements in healthcare through scientific research and collaboration. Read More
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately.
MiNK Therapeutics Q2 2025 earnings miss EPS estimates with a $1.06 loss per share, but cash runway extends to mid-2026. Clinical progress in cancer and GvHD offers future potential.
NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
